nct_id stringlengths 11 11 | title stringlengths 23 300 | phase stringclasses 9
values | status stringclasses 13
values | study_type stringclasses 2
values | is_expanded_access bool 2
classes | sponsor stringlengths 5 100 | summary stringlengths 45 4.76k | interventions listlengths 1 12 | start_date stringlengths 0 10 | url stringlengths 44 44 | target_entities listlengths 0 5 | locations listlengths 0 104 | contact_phone stringlengths 0 29 | contact_email stringlengths 0 41 | eligibility dict | mechanism_summary dict |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NCT06363357 | The Effect of a Muscle-mimicking, Fabric-type Shoulder Orthosis on Functional Movements of the Upper Limb in Patients With Neuromuscular Disorder | NA | COMPLETED | INTERVENTIONAL | false | Seoul National University Hospital | The goal of this clinical trial is to investigate the effect of a muscle-mimicking, fabric-type shoulder orthosis on functional movements of the upper limb in patients with neuromuscular disorder.
The main questions it aims to answer are:
* What is the impact of the muscle-mimicking, fabric-type shoulder orthosis on ... | [
{
"type": "DEVICE",
"name": "Shoulder orthosis"
}
] | 2024-04-20 | https://clinicaltrials.gov/study/NCT06363357 | [] | [
{
"facility": "Seoul National University Hospital",
"city": "Seoul",
"state": "Jongno-gu",
"country": "South Korea",
"status": "",
"lat": 37.566,
"lon": 126.9784
}
] | null | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT04821479 | Repeated Mesenchymal Stem Cell Injections in ALS | PHASE1, PHASE2 | COMPLETED | INTERVENTIONAL | false | Hadassah Medical Organization | An open-label, single-center clinical trial to evaluate the safety and efficacy of repeated intrathecal administrations of autologous bone marrow derived mesenchyme stem cells in ALS patients. The study includes 20 subjects (age: 20-70) with definite diagnosis of ALS and ALS-FRS-R score of at least 20 and disease-durat... | [
{
"type": "BIOLOGICAL",
"name": "Mesenchymal stem cells (MSC)"
}
] | 2016-01-01 | https://clinicaltrials.gov/study/NCT04821479 | [
"neuroinflammation"
] | [] | null | {
"compound": "Mesenchymal stem cells (MSC)",
"targeting_mechanism": "Bone marrow-derived mesenchymal stem cells provide trophic support and anti-inflammatory effects by differentiating into support cells and producing growth factors and anti-inflammatory cytokines.",
"targeting_mechanism_pmid": "32043626",
"an... | ||
NCT00647296 | Safety and Tolerability Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | COMPLETED | INTERVENTIONAL | false | Knopp Biosciences | This was a 2-part study of dexpramipexole in patients with ALS.
Part 1 was a randomized, placebo-controlled, multi-center study to evaluate the safety, tolerability, and clinical effects of oral administration of 3 dosage levels of dexpramipexole vs. placebo for 12 weeks.
Part 2 was a randomized, double-blind, 2-arm,... | [
{
"type": "DRUG",
"name": "Placebo"
},
{
"type": "DRUG",
"name": "Dexpramipexole 50 mg/day"
},
{
"type": "DRUG",
"name": "Dexpramipexole 150 mg/day"
},
{
"type": "DRUG",
"name": "Dexpramipexole 300 mg/day"
}
] | 2008-04-09 | https://clinicaltrials.gov/study/NCT00647296 | [
"mitochondrial_function"
] | [
{
"facility": "University of Arkansas for Medical Sciences",
"city": "Little Rock",
"state": "Arkansas",
"country": "United States",
"status": "",
"lat": 34.74648,
"lon": -92.28959
},
{
"facility": "UCLA, Dept. of Neurology - Neuromuscular/ALS Research Center",
"city": "Los A... | null | {
"compound": "Dexpramipexole",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT01854294 | GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS) | PHASE2 | COMPLETED | INTERVENTIONAL | false | Genervon Biopharmaceuticals, LLC | GM604 is an endogenous human embryonic stage neural regulatory and signaling peptide that controls the development, monitoring and correction of the human nervous system. Neurological diseases are multisystem, multifactorial, and single target drugs are ineffective. Genervon's Master Regulators play a significant role ... | [
{
"type": "DRUG",
"name": "GM604"
},
{
"type": "DRUG",
"name": "Placebo comparator"
}
] | 2013-08 | https://clinicaltrials.gov/study/NCT01854294 | [
"neuroinflammation"
] | [
{
"facility": "Massachusetts General Hospital",
"city": "Boston",
"state": "Massachusetts",
"country": "United States",
"status": "",
"lat": 42.35843,
"lon": -71.05977
},
{
"facility": "Columbia Medical Center NY",
"city": "New York",
"state": "New York",
"country": "... | null | {
"compound": "GM604",
"targeting_mechanism": "GM604 is an endogenous human embryonic stage neural regulatory and signaling peptide that modulates multiple pathways including inflammation, apoptotic, and hypoxia signaling.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "... | ||
NCT06365216 | ALS Phase II Study of NX210c | PHASE2 | ACTIVE_NOT_RECRUITING | INTERVENTIONAL | false | Axoltis Pharma | This study will investigate the efficacy, safety, tolerability and pharmacokinetics (PK) of multiple intravenous infusions of NX210c, at two dose levels, in patients with Amyotrophic lateral sclerosis (ALS). | [
{
"type": "DRUG",
"name": "NX210c"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2024-10-25 | https://clinicaltrials.gov/study/NCT06365216 | [
"GLT1"
] | [
{
"facility": "Centre Hospitalier Regional Et Universitaire De Brest",
"city": "Brest",
"state": "France",
"country": "France",
"status": "",
"lat": 48.39029,
"lon": -4.48628
},
{
"facility": "Centre Hospitalier Universitaire De Caen Normandie",
"city": "Caen",
"state": "... | null | {
"compound": "NX210c",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT07813858 | Colchicine Effect on Amyotrophic Lateral Sclerosis Patients | PHASE2 | NOT_YET_RECRUITING | INTERVENTIONAL | false | Azienda Ospedaliero-Universitaria di Modena | The goal of this clinical trial is to evaluate whether low-dose colchicine can slow disease progression in patients with amyotrophic lateral sclerosis (ALS), a progressive and fatal neurodegenerative disorder affecting motor neurons.
The study is designed to answer whether patients receiving colchicine show a slower d... | [
{
"type": "DRUG",
"name": "Colchicine 0.5 MG Oral Tablet"
},
{
"type": "DRUG",
"name": "Placebo Oral Tablet"
}
] | 2026-10 | https://clinicaltrials.gov/study/NCT07813858 | [
"neuroinflammation"
] | [
{
"facility": "Centro Clinico Nemo",
"city": "Milan",
"state": "Milano",
"country": "Italy",
"status": "",
"lat": 42.78235,
"lon": 12.59836
},
{
"facility": "CENTRO SLA, Ospedale Civile di Baggiovara, AOU Modena",
"city": "Modena",
"state": "Modena",
"country": "Italy... | 059-3961640 | gianferrari.giulia@aou.mo.it | null | {
"compound": "Colchicine 0.5 MG",
"targeting_mechanism": "Reduces neuroinflammation by modulating inflammatory responses in neurodegenerative disease.",
"targeting_mechanism_pmid": "28872464",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""... |
NCT05279755 | A Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of Prosetin in Healthy Volunteers and Participants With ALS | PHASE1 | ACTIVE_NOT_RECRUITING | INTERVENTIONAL | false | ProJenX | The primary purpose of this study is to evaluate the safety and tolerability of prosetin in healthy volunteers and participants with ALS. | [
{
"type": "DRUG",
"name": "prosetin"
},
{
"type": "DRUG",
"name": "placebo"
}
] | 2022-02-26 | https://clinicaltrials.gov/study/NCT05279755 | [
"SOD1"
] | [
{
"facility": "Massachusetts General Hospital",
"city": "Boston",
"state": "Massachusetts",
"country": "United States",
"status": "",
"lat": 42.35843,
"lon": -71.05977
},
{
"facility": "Worldwide Clinical Trials Early Phase Services",
"city": "San Antonio",
"state": "Texa... | null | {
"compound": "prosetin",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT00694941 | A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | COMPLETED | INTERVENTIONAL | false | Ono Pharmaceutical Co., Ltd. | The objective of this study is to investigate the long term safety of ALS patients taking ONO-2506PO. | [
{
"type": "DRUG",
"name": "ONO-2506PO"
}
] | 2008-06 | https://clinicaltrials.gov/study/NCT00694941 | [
"neuroinflammation"
] | [
{
"facility": "Prof. Maloteaux, UCL Saint-Luc",
"city": "Brussels",
"state": "",
"country": "Belgium",
"status": "",
"lat": 50.85045,
"lon": 4.34878
},
{
"facility": "Prof. Wim Robberecht, UZ Leuven",
"city": "Leuven",
"state": "",
"country": "Belgium",
"status": ... | null | {
"compound": "ONO-2506PO",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT05358431 | Stratification of Presymptomatic Amyotrophic Lateral Sclerosis: the Development of Novel Imaging Biomarkers | NA | UNKNOWN | INTERVENTIONAL | false | Assistance Publique - Hôpitaux de Paris | Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive neurodegenerative disorder with no effective disease-modifying therapies at present. The disease is sporadic in 90 % of the ALS patients. Up to 40 % familial ALS cases and up to 25% of familial frontotemporal dementia (FTD) are caused by autosomal domina... | [
{
"type": "OTHER",
"name": "Neuroimaging and electrophysiology"
}
] | 2022-07-21 | https://clinicaltrials.gov/study/NCT05358431 | [
"C9orf72"
] | [
{
"facility": "ICM, GH Pitié-Salpêtrière",
"city": "Paris",
"state": "",
"country": "France",
"status": "RECRUITING",
"lat": 48.85341,
"lon": 2.3488
}
] | 1.42.16.24.71 | pierre-francois.pradat@aphp.fr | null | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT01041222 | Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene Mutations | PHASE1 | COMPLETED | INTERVENTIONAL | false | Ionis Pharmaceuticals, Inc. | This study will test the safety, tolerability and pharmacokinetics of single doses of ISIS 333611 administered into the spinal canal as 12 hour infusions. | [
{
"type": "DRUG",
"name": "ISIS 333611"
}
] | 2010-01 | https://clinicaltrials.gov/study/NCT01041222 | [
"SOD1"
] | [
{
"facility": "Johns Hopkins University",
"city": "Baltimore",
"state": "Maryland",
"country": "United States",
"status": "",
"lat": 39.29038,
"lon": -76.61219
},
{
"facility": "Massachusetts General Hospital-East, Neurology Clinical Trials Unit",
"city": "Charlestown",
"... | null | {
"compound": "ISIS 333611",
"targeting_mechanism": "Antisense oligonucleotide targeting SOD1 mRNA to reduce superoxide dismutase 1 protein levels in SOD1 mutant familial ALS.",
"targeting_mechanism_pmid": "29751510",
"animal_results": "Artificial microRNA targeting SOD1 extends survival and delays paralysis in... | ||
NCT01511029 | Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate) | PHASE1 | COMPLETED | INTERVENTIONAL | false | Knopp Biosciences | To evaluate whether dexpramipexole prolongs the QTc interval when orally administered to healthy volunteers. | [
{
"type": "DRUG",
"name": "Dexpramipexole"
},
{
"type": "DRUG",
"name": "Dexpramipexole"
},
{
"type": "DRUG",
"name": "Dexpramipexole Placebo"
},
{
"type": "DRUG",
"name": "Moxifloxacin"
}
] | 2012-01 | https://clinicaltrials.gov/study/NCT01511029 | [
"dexpramipexole"
] | [
{
"facility": "Research Site",
"city": "Overland Park",
"state": "Kansas",
"country": "United States",
"status": "",
"lat": 38.98223,
"lon": -94.67079
}
] | null | {
"compound": "Dexpramipexole",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT03580616 | Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | TERMINATED | INTERVENTIONAL | false | Elijah W. Stommel | The purpose of this study is to determine the tolerability of L-Serine oral doses for ALS patients and assess preliminary indications of efficacy | [
{
"type": "DRUG",
"name": "L-Serine"
}
] | 2018-10-24 | https://clinicaltrials.gov/study/NCT03580616 | [
"serine_metabolism"
] | [
{
"facility": "Dartmouth-Hitchcock Medical Center",
"city": "Lebanon",
"state": "New Hampshire",
"country": "United States",
"status": "",
"lat": 43.64229,
"lon": -72.25176
}
] | null | {
"compound": "L-Serine",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT05297487 | Evaluation of the Early Use of the Pressure Relaxer in the Respiratory Impairment of Patients With Amyotrophic Lateral Sclerosis: Multicenter Randomized Controlled Study. | NA | NOT_YET_RECRUITING | INTERVENTIONAL | false | Centre Hospitalier Universitaire de la Réunion | Amyotrophic lateral sclerosis (ALS) is a rare and serious neurodegenerative disease causing degeneration of motor neurons. . It leads to a progressive paralysis of the muscles involved in voluntary motricity. In France, its incidence is 2.5/100,000 inhabitants per year.
The death of patients is mainly caused by a prog... | [
{
"type": "DEVICE",
"name": "early use of intermittent positive pressure breathing"
}
] | 2025-07-01 | https://clinicaltrials.gov/study/NCT05297487 | [] | [] | null | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT06181526 | Safety and Preliminary Efficacy of Aleeto in Amyotrophic Lateral Sclerosis | PHASE1 | UNKNOWN | INTERVENTIONAL | false | Beijing Tiantan Hospital | This study is a single-center, randomized, double-blind, placebo parallel-controlled, dose-escalation clinical study. The aim of this study was to evaluate the safety, tolerability, and preliminary effect of Aleeto in adult patients with ALS, and to provide an appropriate dose for the future clinical trial. | [
{
"type": "DRUG",
"name": "Aleeto"
},
{
"type": "DEVICE",
"name": "intravenous injection"
},
{
"type": "DEVICE",
"name": "intrathecal injection"
}
] | 2023-12-15 | https://clinicaltrials.gov/study/NCT06181526 | [
"aleeto"
] | [
{
"facility": "Beijing Tiantan Hospital",
"city": "Beijing",
"state": "",
"country": "China",
"status": "",
"lat": 39.9075,
"lon": 116.39723
}
] | 13911666571 | yilong528@gmail.com | null | {
"compound": "Aleeto",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT02709330 | ALS Reversals - Lunasin Regimen | PHASE2 | COMPLETED | INTERVENTIONAL | false | Richard Bedlack, M.D., Ph.D. | This is a 12-month, widely inclusive, largely virtual, single-center, open-label pilot trial utilizing a historical control group. Participants will receive a Lunasin regimen and will be asked to register for an account of PatientsLikeMe website, where after the initial in-clinic visit, they will be asked to enter spec... | [
{
"type": "DRUG",
"name": "Lunasin Regimen"
},
{
"type": "OTHER",
"name": "Historical control"
}
] | 2016-04 | https://clinicaltrials.gov/study/NCT02709330 | [
"lunasin"
] | [
{
"facility": "Duke Medicine / Neurology",
"city": "Durham",
"state": "North Carolina",
"country": "United States",
"status": "",
"lat": 35.99403,
"lon": -78.89862
}
] | null | {
"compound": "Lunasin",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT07380204 | Quantification of Hsp90 in the Human Brain | NA | RECRUITING | INTERVENTIONAL | false | Universitaire Ziekenhuizen KU Leuven | This study tests the radiolabeled molecule ("tracer"), \[¹¹C\]HSP990, using positron emission tomography (PET) imaging to assess whether it can be used to measure levels of Heat Shock Protein 90 (Hsp90). The protein Hsp90 plays an important role in how proteins in the brain fold into their three-dimensional structure a... | [
{
"type": "OTHER",
"name": "[11C]HSP990 PET dosimetry"
},
{
"type": "OTHER",
"name": "[11C]HSP990 PET test-retest"
},
{
"type": "OTHER",
"name": "[11C]HSP990 simplified scan protocol"
}
] | 2024-09-04 | https://clinicaltrials.gov/study/NCT07380204 | [
"HSP90"
] | [
{
"facility": "UZ Leuven",
"city": "Leuven",
"state": "Vlaam-Brabant",
"country": "Belgium",
"status": "RECRUITING",
"lat": 50.87959,
"lon": 4.70093
}
] | +32 16 34 37 15 | koen.vanlaere@uzleuven.be | null | {
"compound": "[11C]HSP990",
"targeting_mechanism": "A positron emission tomography (PET) imaging tracer for quantifying Heat Shock Protein 90 (Hsp90), a molecular chaperone involved in protein folding and cellular homeostasis in the brain.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"anima... |
NCT05006352 | A Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL343 in Participants With Amyotrophic Lateral Sclerosis | PHASE1 | COMPLETED | INTERVENTIONAL | false | Denali Therapeutics Inc. | This is a Phase 1b, multicenter, randomized, placebo-controlled, double-blind study of 28 days, followed by an 18-month open-label extension, designed to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of DNL343 in participants with amyotrophic lateral sclerosis (ALS) | [
{
"type": "DRUG",
"name": "DNL343"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2021-08-11 | https://clinicaltrials.gov/study/NCT05006352 | [
"dnl343"
] | [
{
"facility": "HonorHealth",
"city": "Scottsdale",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.50921,
"lon": -111.89903
},
{
"facility": "University of California at San Diego",
"city": "San Diego",
"state": "California",
"country": "United... | null | {
"compound": "DNL343",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT00136110 | Trial of Sodium Valproate in Amyotrophic Lateral Sclerosis | PHASE3 | COMPLETED | INTERVENTIONAL | false | UMC Utrecht | The purpose of this study is to determine whether the use of sodium valproate is effective in slowing the disease progression in Amyotrophic Lateral Sclerosis. | [
{
"type": "DRUG",
"name": "Sodium Valproate"
}
] | 2005-04 | https://clinicaltrials.gov/study/NCT00136110 | [
"HDAC"
] | [
{
"facility": "UMC Utrecht",
"city": "Utrecht",
"state": "Utrecht",
"country": "Netherlands",
"status": "",
"lat": 52.09083,
"lon": 5.12222
}
] | null | {
"compound": "Sodium Valproate",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT07680361 | Study of Home Use of the Jaco Robotic Manipulation Device by Individuals With Tetraplegia | NA | COMPLETED | INTERVENTIONAL | false | Association APPROCHE | For all individuals deprived of active and functional motor control of the upper limbs to perform grasping tasks, the restoration of a grasping function becomes a priority.
The population concerned is mainly represented by so-called functional tetraplegic individuals.
In this context, new technologies, and more parti... | [
{
"type": "DEVICE",
"name": "Use of the JACO robotic arm for a period of 2 months"
}
] | 2022-03-30 | https://clinicaltrials.gov/study/NCT07680361 | [] | [
{
"facility": "Centre Bouffard Vercelli",
"city": "Perpignan",
"state": "",
"country": "France",
"status": "",
"lat": 42.69764,
"lon": 2.89541
}
] | null | {
"compound": "JACO robotic arm",
"targeting_mechanism": "An assistive robotic manipulation device designed to restore and compensate for loss of active motor control of upper limbs in individuals with functional tetraplegia.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid"... | ||
NCT03214224 | Remote Pulmonary Function Testing in Amyotrophic Lateral Sclerosis (Pilot) | NA | COMPLETED | INTERVENTIONAL | false | Milton S. Hershey Medical Center | The specific objective of this study is to validate the practice of remote pulmonary function testing (rPFT) conducted in the home through the use of connected mobile health devices and the Penn State Hershey ALS Telemanagement program. | [
{
"type": "DEVICE",
"name": "remote pulmonary function testing"
},
{
"type": "DEVICE",
"name": "standard pulmonary function testing"
}
] | 2017-11-01 | https://clinicaltrials.gov/study/NCT03214224 | [] | [
{
"facility": "Hershey Medical Center ALS Clinic",
"city": "Hershey",
"state": "Pennsylvania",
"country": "United States",
"status": "",
"lat": 40.28592,
"lon": -76.65025
}
] | null | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT03201991 | ALS Study Determining Various Biomarkers and Strength Comparison After Exercise | NA | COMPLETED | INTERVENTIONAL | false | University of Kansas Medical Center | The purpose of this study is to determine the muscle strength of a muscle in the thigh after 12 weeks of home exercise. | [
{
"type": "OTHER",
"name": "Resistance Exercise Program"
}
] | 2017-05-01 | https://clinicaltrials.gov/study/NCT03201991 | [] | [
{
"facility": "University of Kansas Medical Center",
"city": "Kansas City",
"state": "Kansas",
"country": "United States",
"status": "",
"lat": 39.11417,
"lon": -94.62746
}
] | null | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT05716074 | The Effect of Low-İntensity Combined Exercises in Patients With Early Stage ALS. | NA | UNKNOWN | INTERVENTIONAL | false | Istanbul University - Cerrahpasa | The aim of this study is to investigate the effects of low-intensity combined exercises on balance, fatigue and quality of life applied to patients with ALS. | [
{
"type": "OTHER",
"name": "Supervised exercise"
},
{
"type": "OTHER",
"name": "Home exercise"
}
] | 2022-11-15 | https://clinicaltrials.gov/study/NCT05716074 | [] | [
{
"facility": "Istanbul University-Cerrahpasa",
"city": "Istanbul",
"state": "Bakirkoy",
"country": "Turkey (Türkiye)",
"status": "RECRUITING",
"lat": 41.01384,
"lon": 28.94966
}
] | +905422175730 | etarakci@iuc.edu.tr | null | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.